Physician profile
Robert L Digiovanni
NPI 1770572778
$19,755.91
in general payments reported to CMS, 2019-2025
58 companies · $3,331 in 2025
The $3,331 reported for 2025 was more than what 79% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,975 · 2020: $2,033 · 2021: $2,896 · 2022: $2,541 · 2023: $2,868 · 2024: $3,111 · 2025: $3,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,026 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,025.53 |
| Education | $284.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,896.75 | 2019-2025 | Rinvoq, Skyrizi, Qulipta |
| Amgen INC. | $2,469.33 | 2019-2025 | Enbrel, Evenity, Otezla |
| Janssen Biotech, INC. | $1,955.52 | 2019-2025 | Tremfya, Stelara, Remicade |
| Pfizer INC. | $1,482.05 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,453.19 | 2019-2025 | |
| Genzyme Corporation | $1,350.15 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,236.07 | 2019-2025 | Benlysta, Nucala, Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $1,065.25 | 2020-2025 | Acthar |
| Ucb, INC. | $676.55 | 2019-2025 | Cimzia, Bimzelx |
| Novo Nordisk INC | $580.09 | 2019-2025 | Rybelsus, Ozempic |
| Genentech USA, INC. | $552.10 | 2019-2023 | Actemra |
| Horizon Therapeutics Plc | $468.08 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $369.86 | 2019-2025 | Orencia |
| Lilly USA, LLC | $357.66 | 2019-2025 | Mounjaro, Taltz, Zepbound |
| Radius Health, INC. | $268.91 | 2019-2025 | Tymlos |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Digiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.